155 related articles for article (PubMed ID: 11907796)
1. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation.
Gemmel C; Cremer FW; Weis M; Witzens M; Moldenhauer G; Koniczek KH; Imbach U; Ho AD; Moos M; Goldschmidt H
Ann Hematol; 2002 Feb; 81(2):119-23. PubMed ID: 11907796
[TBL] [Abstract][Full Text] [Related]
2. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation.
Kiel K; Cremer FW; Rottenburger C; Kallmeyer C; Ehrbrecht E; Atzberger A; Hegenbart U; Goldschmidt H; Moos M
Bone Marrow Transplant; 1999 May; 23(10):1019-27. PubMed ID: 10373068
[TBL] [Abstract][Full Text] [Related]
3. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation.
Lipinski E; Cremer FW; Ho AD; Goldschmidt H; Moos M
Bone Marrow Transplant; 2001 Nov; 28(10):957-62. PubMed ID: 11753551
[TBL] [Abstract][Full Text] [Related]
4. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support.
Boccadoro M; Omedé P; Dominietto A; Palumbo A; Bringhen S; Giaretta F; Ortolano B; Triolo S; Pileri A
Bone Marrow Transplant; 2000 Jan; 25(1):25-9. PubMed ID: 10654010
[TBL] [Abstract][Full Text] [Related]
6. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature.
Hovenga S; de Wolf JT; Klip H; Vellenga E
Bone Marrow Transplant; 1997 Nov; 20(10):901-4. PubMed ID: 9404934
[TBL] [Abstract][Full Text] [Related]
7. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
8. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
10. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma.
Cremer FW; Ehrbrecht E; Kiel K; Benner A; Hegenbart U; Ho AD; Goldschmidt H; Moos M
Bone Marrow Transplant; 2000 Oct; 26(8):851-8. PubMed ID: 11081384
[TBL] [Abstract][Full Text] [Related]
12. [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation].
Abe T; Kitajima T; Honma K; Kurasaki T; Okazuka K; Shibasaki Y; Momoi A; Kuroha T; Masuko M; Yagisawa K; Furukawa T; Toba K; Aizawa Y
Rinsho Ketsueki; 2008 Nov; 49(11):1556-61. PubMed ID: 19047788
[TBL] [Abstract][Full Text] [Related]
13. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
[TBL] [Abstract][Full Text] [Related]
14. [Long-term complete remission in primary plasma cell leukemia after treatment with VAD chemotherapy and tandem autologous peripheral blood stem cell transplantation].
Iino M; Nakajima A; Shindo H
Gan To Kagaku Ryoho; 2008 Dec; 35(13):2441-3. PubMed ID: 19098420
[TBL] [Abstract][Full Text] [Related]
15. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
Flohr T; Hess G; Kolbe K; Gamm H; Nolte H; Stanislawski T; Huber C; Derigs HG
Bone Marrow Transplant; 2002 May; 29(9):769-75. PubMed ID: 12040475
[TBL] [Abstract][Full Text] [Related]
17. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia.
Jándula BM; Nomdedeu J; Marín P; Vivancos P
Bone Marrow Transplant; 2001 Jan; 27(2):225-7. PubMed ID: 11281397
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
19. Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas.
Tóthová E; Kafková A; Guman T; Stecová N; Fricová M
Neoplasma; 2003; 50(1):22-5. PubMed ID: 12687274
[TBL] [Abstract][Full Text] [Related]
20. Early relapse after rituximab chemoimmunotherapy.
Kiss F; Buslig J; Szegedi I; Scholtz B; Kappelmayer J; Kiss C
Pediatr Blood Cancer; 2008 Feb; 50(2):372-5. PubMed ID: 17973316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]